# **HEME:** A Self-Improving Computer Program for Diagnosis-Oriented Analysis of Hematologic Diseases

Abstract: Heme, a computer program for diagnosis-oriented analysis of hematologic diseases, accepts as input information about a patient and provides as output an ordered list of suggested diagnoses, an analysis of the logic behind these diagnoses, and a list of tests relevant to these diagnoses and not yet performed. The decision algorithm is based on Bayes' Theorem. Each disease in the system is individually analyzed, and the probability that the patient has the disease vs the probability that he does not is calculated. Bayesian methods of statistical inference are utilized in that the prior probabilities of the diseases and the probabilities of findings in given diseases were initially estimated from the judgment of experienced hematologists with the intention that they be modified automatically as data are accumulated. This program is intended for use in teaching hematology, as an aid to diagnosis, and as a means for studying the diagnostic process.

#### Introduction

HEME is a computer program that was conceived and developed to use Bayes' Theorem and Bayesian methods of inference for diagnosis-oriented analysis of hematologic diseases. It may be used by physicians to suggest diagnoses, to remind them of available test procedures, and to check their thinking at each stage of the diagnostic process. HEME is also useful as a teaching tool to train students in hematology and in methods of interacting with a computer. The program is a vehicle for identifying those features that are vital to the diagnostic process.

For more than twenty years physicians and computer scientists have been trying to produce useful computer aids to diagnosis. Our work on aids to diagnosis of hematologic diseases was initiated in 1952 when Lipkin and Hardy used McBee marginal punched cards to match the findings about a patient with a predetermined set of findings thought to characterize each of the 27 hematologic diseases in the system. A hand-operated mechanical sorting process selected those diseases for which the findings best matched those of a patient, and a score was calculated for the patient's findings in relation to each of the selected diseases [1-3]. Using these same principles our group of investigators organized by Zworykin and Lipkin developed a computer program to sort the data and print out information about the matching of a patient's findings with findings characteristic of diseases. The first demonstration of this system on a computer in 1957 applied to 20 hematologic diseases [4-8]. Later, the group developed a larger system. A thorough literature search resulted in the tabulation of incidence figures for the important findings in 75 hematologic diseases [9]. We used the incidence figures to estimate weights for each of 540 findings in each disease, and we developed algorithms to utilize these weights to calculate scores for a patient's findings in relation to each disease [10-11]. The incidence and weight tables from these previous studies were used to help in arriving at the value judgments required for the Bayesian program initiated in 1967 [11] and reported in this paper. Portions of this work have been presented at meetings [12-14].

Many investigators have used decision theory in medical diagnosis. Ledley and Lusted in 1959 [15] in a major contribution discussed the logic of medical diagnosis and the application of symbolic logic, probability, and value theory in medical decision making. They introduced the use of decision trees in diagnosis and suggested the use of Bayes' Theorem in medicine. Their paper provided considerable stimulus to us and other workers. Much subsequent work has been the elaboration and practical application of their ideas. By 1961 Warner, Toronto, Veasey, and Stephenson [16] had applied Bayes' Theorem to the diagnosis of 33 congenital heart diseases using 50 findings [17-18]. In addition to the contributions of many other investigators, significant ideas in the field of medical decision making came from Gorry and Barnett [19], who applied sequential decision theory to diagnostic problems, and from Gustafson [20], who experimented with subjective judgment in the estimation of probabilities.

### Description of HEME

The HEME program performs probabilistic calculations that relate a patient's findings to the diagnosis of hematologic diseases. It contains the following elements:

557

Table 1 Hematologic diseases presently used in HEME program.

- 01 AGRANULOCYTOSIS 02 ANEMIA OF MALABSORPTION SYNDROME 03 APLASTIC ANEMIA 04 CHRONIC MYELOGENOUS LEUKEMIA 05 IRON DEFICIENCY ANEMIA 06 MULTIPLE MYELOMA 07 POLYCYTHEMIA VERA 08 PERNICIOUS ANEMIA 09 MEGALOBLASTIC ANEMIA OF PREGNANCY 10 INFECTIOUS MONONLICLEOSIS 11 DRUG INDUCED HEMOLYTIC ANEMIA 12 SICKLE CELL ANEMIA
- 13 SICKLE CELL TRAIT 14 HODGKIN'S DISEASE 15 ACUTE LEUKEMIA 16 LYMPHOSARCOMA 17 IDIOPATHIC THROMBOCYTOPENIC PURPURA 18 SECONDARY POLYCYTHEMIA
- 19 ANEMIA OF LIVER DISEASE 20 CHRONIC LYMPHATIC LEUKEMIA
- 21 RETICULUM CELL SARCOMA 22 GAUCHER'S DISEASE 23 FACTOR VIII DEFICIENCY
- 24 HEREDITARY SPHEROCYTOSIS
- 25 ERYTHROBLASTOSIS FETALIS 26 ANEMIA OF INFECTION
- 27 HEMOCHROMATOSIS 28 LUPUS ERYTHEMATOSUS
- 29 THALASSEMIA MAJOR 30 THALASSEMIA MINOR
- 31 NIEMANN-PICK DISEASE
- 32 GIANT FOLLICULAR LYMPHOMA
- 33 CONGENITAL AFIBRINOGENEMIA
- 34 CONGENITAL SEX-LINKED AGAMMAGLOBULINEMIA
- 35 CONGENITAL SWISS-TYPE AGAMMAGLOBULINEMIA
- 36 ANEMIA OF HYPOTHYROIDISM
- 37 NONHEMOLYTIC ANEMIA OF MALIGNANCY
- 38 THROMBOTIC THROMBOCYTOPENIC PURPURA
- 39 PRIMARY IDIOPATHIC NON-TROPICAL HYPERSPLENISM
- 40 ACQUIRED IDIOPATHIC REFRACTORY SIDEROBLASTIC ANEMIA
- 1. A list of diseases that may be diagnosed along with the frequency Φ, with which these diseases occur in the population under consideration. The present list of 40 diseases appears in Table 1. The frequencies are those that are thought to occur on the hematology service of the New York Hospital; they may be modified through Bayesian inference as data are accumulated.
- 2. A list of descriptors considered relevant to the diagnosis of hematologic diseases. A descriptor is defined as a property to be described by the patient (demographic characteristic or symptom), observed by the physician (sign), or measured in the laboratory (laboratory characteristic). Typical descriptors are sex, blood pressure, hepatosplenomegaly, abdominal pain, and leukocyte count.
- 3. For each descriptor a finite number of findings that are thought to characterize the clinically significant states

that the descriptor may assume. These findings must be mutually exclusive and exhaustive, so that each patient may be characterized by one and only one finding for each descriptor. The absence of a sign or symptom is itself a finding. Findings corresponding to the above descriptors are:

Descriptor	Findings	
Sex	Male; female	
Blood pressure	Normal; high; low	
Hepatosplenomegaly	Neither; liver only;	
	spleen only; both	
	(enlarged)	
Abdominal pain	Absent (-); present (+)	
Leukocyte count	<3000; 3000-4999;	
	5000-9999; 10000-	
	49999; 50000-99999;	
	≥100000	

In Table 2, 58 of the 585 findings presently used are listed.

- 4. For each disease and for each finding relevant to that disease, there are two probabilities, also known as likelihoods, defined as follows:
- $p_{ii}$  is the probability that a ptaient with disease i has finding j at the time when the disease is diagnosed.
- $q_{ij}$  is the probability that a patient who does not have disease i, but for whom the descriptor corresponding to finding i is observed during the diagnostic process, does have finding j at the time of observation.

Both these probabilities refer to patients on the hematology service at the New York Hospital.

Initally, the  $p_{ij}$  and  $q_{ij}$  were estimated from the judgment of the clinicians responsible for the program, based on frequency data that were previously collected [9]. Each estimate has been recorded as the ratio of two integers, parameters of a prior distribution from the beta class, i.e.,

$$p_{ij} = m_{ij}/n_i; \qquad q_{ij} = r_{ij}/s_i.$$

In this scheme the clinician not only guesses values for p and q but he also indicates numerically how sure he is of his guess. The larger the values of the numerator and denominator the more certain is the estimate of p or q, i.e., the smaller is the variance of the prior distribution. Suppose, for example, the frequency of some finding in a given disease is thought to be one in ten. If the physician were quite confident of that, he might set  $m_{ij}$  at 1000 and  $n_i$  at 10000. On the other hand, if he were very unsure of his guess, he might set  $m_i$  at 1 and  $n_i$  at 10. It is intended that these estimates be modified automatically from information in the Patient Data File described in item 6 below.

5. Bayes' Theorem, as used in the HEME program, computes, for each disease, the probability that the patient has that disease vs the probability that he does not, i.e.,

Prob (disease i/findings) =

 $\Phi_i$  Prob (findings/disease i)

 $\div [\Phi_i \text{ Prob (findings/disease } i)]$ 

+  $(1 - \Phi_i)$  Prob (findings/not disease i)].

Assuming that the findings are mutually independent, we set

Prob (findings/disease 
$$i$$
) =  $\prod_{\text{findings}} p_{ij}$ ;

Prob (findings/not disease 
$$i$$
) =  $\prod_{\text{findings}} q_{ij}$ .

The question of independence and our efforts to approximate it are discussed later under the heading "Independence."

We now have the version of Bayes' Theorem that is incorporated into the HEME program:

$$\text{Prob (disease } i/\text{findings}) = \frac{\Phi_i \; \Pi \; p_{ij}}{\Phi_i \; \Pi \; p_{ij} + (1 - \Phi_i) \; \Pi \; q_{ij}}.$$

Each product is taken over all the patient's findings.

Dividing both numerator and denominator in the previous expression by  $(1 - \Phi_i) \prod q_{ij}$  we find:

Prob (disease i/findings) =

$$\frac{\left[\Phi_{i}/\left(1-\Phi_{i}\right)\right] \; \Pi \; \left(p_{ij}/q_{ij}\right)}{\left[\Phi_{i}/\left(1-\Phi_{i}\right)\right] \; \Pi \; \left(p_{ij}/q_{ij}\right) \; + \; 1}.$$

We can observe from this equation that it is the quantity  $p_{ij}/q_{ij}$ , the likelihood ratio of disease i in relation to finding j, that indicates the effect of the observation of a finding on the diagnosis of a disease. Thus, if  $p_{ij}/q_{ij}$  is much larger than 1, the observation of the finding tends to lead to the diagnosis of the disease; if  $p_{ij}/q_{ij}$  is much smaller than 1, the finding tends to rule out the disease; and if  $p_{ij}/q_{ij}$  is close to 1, the finding has little relevance to the diagnosis of the disease.

The version of Bayes' Theorem presented here was used by Nugent and co-workers for the decision of whether or not a patient had Cushing's Syndrome [21]. Our group has initiated its use in making simultaneous decisions about whether or not a patient has each of a wide range of diseases. In this version Bayes' Theorem is applied separately for each disease, and each time it is used it refers to a universe that consists of only two groups, patients who have the given disease and patients who do not have the disease. The patients who do not have the disease belong to the specified population of patients under consideration, and they may have some

Table 2 Portion of list of findings presently used in HEME program.

PERIPHERAL BLOOD (PB) MORPHOLOGY

	268+	RBC INDICES HGB <7 , MCV >94, MCH >30
	269+	RBC INDICES HGB $<7$ , MCV 80-94, MCH $>30$
	270+	RBC INDICES HGB $<7$ , MCV $<80$ , MCH $>30$
	271+	RBC INDICES HGB <7, MCV <80, MCH <30
	272+	RBC INDICES HGB 7-12.9, MCV >94, MCH >30
	273+	RBC INDICES HGB 7-12.9, MCV 80-94, MCH >30
	274+	RBC INDICES HGB 7-12.9, MCV <80, MCH >30
	275+	RBC INDICES HGB 7-12.9, MCV <80, MCH <30
	276+	
	277+	RBC INDICES HGB >17, RBC >5, PCV >50
	278+	LEUKOCYTE COUNT <3000
	279+	LEUKOCYTE COUNT 3,000-4,999
	280 +	LEUKOCYTE COUNT 5,000-9,999
	281 +	LEUKOCYTE COUNT 10,000-49,999
	282 +	LEUKOCYTE COUNT 50,000-99,999
	283+	LEUKOCYTE COUNT ≥100,000
	284+	LYMPHOCYTES <20%
	285+	LYMPHOCYTES 20-39%
	286+	LYMPHOCYTES 40-59%
	287+	LYMPHOCYTES 60-79%
	288+	LYMPHOCYTES ≥80%
	2001	EIMINOCIES 2007
	289+	LYMPHOCYTES ATYP IN PB-NONE
	290+	Lymphocytes atyp in PB $< 10\%$ total lymphs
	291+	Lymphocytes atyp in pb $\geq 10\%$ total lymphs
292-	202	
	293±	MONOCYTES $> 5\%$
	295+	MONOCYTES > 5% EOSINOPHILS > 3%  GRANULOCYTES (NEUT, EOSIN, BASOPHILS) <2%
294—	295+	EOSINOPHILS > 3%
294—	295+ 296+ 297+ 298+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS) 50-69%
300-	295+ 296+ 297+ 298+ 299+ 301+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED
300-	295+ 296+ 297+ 298+ 299+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  270%
300-	295+ 296+ 297+ 298+ 299+ 301+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%
300-	295+ 296+ 297+ 298+ 299+ 301+ 303+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB  NONE
300-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB BLASTS, PROMYEL., PROLYMPH. IN PB 0-9%
300-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 10-49%
300- 302-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 306+ 307+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  PROBLEM STORM
300- 302- 308-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 309+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB ≥50%  ANISOCYTOSIS & POIKILOCYTOSIS
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 306+ 307+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS) GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  PROBLEM STORM
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 309+ 311+ 313+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB  ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 306+ 311+ 313+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB ≥50%  ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB − ABSENT
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 311+ 313+ 314+ 315+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB − ABSENT SPHEROCYTES IN PB − OCCASIONAL
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 306+ 311+ 313+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB ≥50%  ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB − ABSENT
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 311+ 313+ 314+ 315+ 316+ 317+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB 250%  ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB − ABSENT SPHEROCYTES IN PB − FREQUENT  PLATELET COUNT <150,000
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 311+ 313+ 314+ 315+ 316+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS) FOR MEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB O- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB ≥50%  ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB — ABSENT SPHEROCYTES IN PB — FREQUENT  PLATELET COUNT <150,000 PLATELET COUNT   150,000 PLATELET COUNT   150,000 PLATELET COUNT   150,000-399,999
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 311+ 313+ 314+ 315+ 316+ 317+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB 250%  ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB − ABSENT SPHEROCYTES IN PB − FREQUENT  PLATELET COUNT <150,000
	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 311+ 313+ 314+ 315+ 316+ 317+ 318+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS) FOR STANDARD STANDA
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 313+ 314+ 315+ 316+ 317+ 318+ 319+ 320+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB − ABSENT SPHEROCYTES IN PB − GCCASIONAL SPHEROCYTES IN PB − FREQUENT  PLATELET COUNT <150,000 PLATELET COUNT   150,000-399,999 PLATELET COUNT   21,000,000
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 311+ 313+ 314+ 315+ 316+ 317+ 318+ 319+ 319+ 319+ 319+ 319+ 319+ 311+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS) ≥70%  NEUTROPHILS HYPERSEGMENTED GRANULOCYTES IMMATURE IN PB > 4%  BLASTS, PROMYEL., PROLYMPH. IN PB 0- 9% BLASTS, PROMYEL., PROLYMPH. IN PB 10-49% BLASTS, PROMYEL., PROLYMPH. IN PB 250%  ANISOCYTOSIS & POIKILOCYTOSIS TARGET CELLS NUCLEATED ERYTHROID CELLS IN PB  SPHEROCYTES IN PB − ABSENT SPHEROCYTES IN PB − CCCASIONAL SPHEROCYTES IN PB − FREQUENT  PLATELET COUNT <150,000 PLATELET COUNT   150,000 PLATELET COUNT   215,000 PLATELET COUNT   21,000,000  RETICULOCYTE COUNT <1%
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 311+ 313+ 315+ 316+ 317+ 318+ 319+ 320+ 321+ 322+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  PROBLEM STORMAN SPHEROCYTES IN PB — ABSENT SPHEROCYTES IN PB — ABSENT SPHEROCYTES IN PB — ABSENT SPHEROCYTES IN PB — FREQUENT  PLATELET COUNT
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 311+ 313+ 316+ 317+ 318+ 319+ 320+ 321+ 322+ 323+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS) FOR STATE OF THE STATE
300- 302- 308- 310-	295+ 296+ 297+ 298+ 299+ 301+ 303+ 304+ 305+ 307+ 311+ 313+ 315+ 316+ 317+ 318+ 319+ 320+ 321+ 322+	GRANULOCYTES (NEUT, EOSIN, BASOPHILS)  PROBLEM STORMAN SPHEROCYTES IN PB — ABSENT SPHEROCYTES IN PB — ABSENT SPHEROCYTES IN PB — ABSENT SPHEROCYTES IN PB — FREQUENT  PLATELET COUNT

other disease or they may be normal. Patients who have the disease might also have one or more other diseases, and allowances for this possibility are made in the estimated values of p. In the usual version the universe consists of patients each of whom has one and only one disease in the system, so that the estimated probabilities of all diseases must sum to one. In our application, the probabilities of all diseases do not add up to one. This version allows for the very real possibility that a patient has more than one disease. Whereas this may not be significant if the system is limited to hematologic diseases, it might be very important in a broader diagnostic scheme. Furthermore, the usual version requires that probabilities be estimated for every finding in every disease, whereas our program contains entries only for those findings considered relevant for each disease. Five-hundred eightyfive findings in 40 diseases would require that 23 400 probabilities be estimated in the usual formulation. Our program uses only about 4000  $p_{ij}/q_{ij}$  ratios. In the following sections the importance of the  $p_{ij}/q_{ij}$  quantities in the use of the program are explained. The significance of these quantities is unique to this version of Bayes' Theorem.

6. It is planned that a Patient Data File be maintained in the computer for the purpose of improving the estimates of the probabilities of findings in diseases and the probabilities of diseases in the population from the feedback of information accumulated through the use of the program. It is intended that, whenever a final diagnosis for a patient is reached by a consensus of physicians responsible for the program, an edited list of all the patient's findings be entered into the computer. The  $p_{ij}$  tables are updated automatically at regular intervals from this file as follows: Suppose the previous value of  $p_{ij}$  was  $m_{ij}/n_i$  and y, new patients with disease i are subsequently diagnosed, of whom  $x_{ij}$  have finding j. Then the new value of  $p_{ij}$  is set at  $(m_{ij} + x_{ij}) / (n_i + y_i)$ . This procedure provides a rational framework in which to combine clinical judgment with data and is based on standard methods of Bayesian inference [22]. As more and more data are accumulated, the facts tend to outweigh the initial clinical judgment in the estimated value of  $p_{ij}$ . Analogous methods may be used to revise values of  $q_{ij}$  and  $\Phi_i$ .

## Independence of findings

A critical step in most applications of Bayes' Theorem is the assumption that findings are independent of one another. This is equivalent to expressing the probability of a complex of findings as the product of the probabilities of the individual findings. This assumption is virtually never strictly fulfilled. Dependence arises in a number of different ways in the medical area. Primarily, it must be realized that all the findings observed in a single patient arise from interrelated mechanisms that developed in the same genetic and environmental setting. It is common for two or more findings that are measured quite separately to be controlled by the identical or closely linked physiological mechanisms. On the one hand, when these mechanisms function normally, many findings are simultaneously maintained in their normal ranges, whereas a single malfunction can be reflected in a number of apparently independent abnormal findings. Pulse rate and body temperature are obvious examples of independently observed descriptors with this kind of physiological dependence.

A second form of dependence occurs when certain descriptors are observed only when specified findings are present. Questions about pregnancy are asked only of females over the age of ten, and lymph node biopsy results are obtained only when other findings lead to the decision to perform a biopsy of the lymph node.

Finally, there is a type of dependence that arises from the man-made organization of diseases. Even if findings are independent in the context of one disease framework, a slight change in the organization of diseases destroys the independence. An example illustrates this point. Consider the disease acute leukemia and its two subdivisions, acute lymphatic leukemia (ALL) and acute myelogenous leukemia (AML). Within each of the two subdivisions considered as separate diseases, it is reasonable to assume that the two findings "Age <20" and "Bone Marrow Shift to Left, Myeloblasts" are independent, so that the probability that a patient has both findings is equal to the product of the probabilities of the individual findings. Now the patient with ALL is most likely younger than 20, say with probability 0.80, and is unlikely to have increased myeloblasts found, say with probability 0.05. The probability that he is younger than 20 and shows increased myeloblasts is then  $0.80 \times 0.05$ or 0.04. On the other hand, in AML the patient is likely to be older and almost surely increased myeloblasts are found in his bone marrow, so we assume the probability of age less than 20 is 0.15 and of increased myeloblasts found is 0.95, so that both are present with a probability of  $0.15 \times 0.95$  or 0.1425.

Now suppose that, instead of considering ALL and AML as distinct disease entities, we merge them and consider only the single disease acute leukemia. We will demonstrate that the two findings "Age <20" and "Bone Marrow Shift to Left, Myeloblasts" are no longer independent in the merged disease. Let 2/3 of the acute leukemics have the lymphatic type and 1/3 have the myelogenous type. We calculate the probabilities of Age <20, increased myeloblasts, and both findings in the mixed disease by taking weighted averages of their probabilities in the individual diseases, i.e., we add 2/3 of the probability in ALL to 1/3 of the probability in AML.

For example, for age <20 we add 2/3 of 0.80 to 1/3 of 0.15 to obtain 0.5833. In similar fashion we find that the probability of increased myeloblasts in the mixed population is 0.35 and of both findings is 0.0742. If age and myeloblasts were independent, the probability of both findings would be equal to the product of 0.5833 and 0.35 or 0.2042, which is 275% of the true probability. Not unexpectedly we find that in a mixed population of people with acute leukemia, ALL or AML, age and bone marrow myeloblasts are not independent. The older members of the population are more likely to have AML and are therefore more likely to have myeloblasts increased.

In general, let us consider two diseases and two findings that are independent within each of these diseases. By a generalization of the reasoning used above it may be proved that, if the two diseases are considered as one, the findings are independent in the merged disease only if the frequency of one of the findings is the same in both diseases [23]. We must bear in mind that the classification of a population into diseases is man-made and is subject to change. Therefore, in any diagnostic system based on Bayes' Theorem an assumption of independence between findings is only an approximation that ordinarily yields results of the correct order of magnitude. In our version of Bayes' Theorem, which uses quantities like  $q_{ij}$ , the probability of finding j in the absence of disease i, the lack of independence between findings could be particularly troublesome, because absence of one disease is a merger of many others. This problem of lack of independence plagues any diagnostic scheme, Bayesian or not, intended to relate a large number of diseases to a large number of findings. The problem of investigating all possible dependencies assumes a magnitude well beyond human understanding or computer capabilities.

One approach to eliminating obvious dependencies is the construction of separate disease-finding tables for different demographic groups, distinguished by sex, age, ethnic group, or geographic location. The more nearly uniform a population with respect to these characteristics, the fewer problems arise due to dependency.

In the HEME program an attempt has been made to eliminate dependencies between findings by coupling descriptors that are known to be highly dependent. For example, instead of considering the liver and spleen separately, we have one descriptor called hepatosplenomegaly, with findings of neither, liver only, spleen only, and both (enlarged). The various measurements of red blood corpuscles (HGB, RBC, and PCV) are considered together and divided into categories considered to have diagnostic significance. An examination of Table 2 shows that we consider normal blood; macrocytic, normocytic, and microcytic anemias of two degrees of severity; and polycythemia as the meaningfully different categories of these correlated measurements. A similar approach to

handling dependencies was recently suggested by Norusis and Jacquez [24, 25].

## Operation of the program

The HEME program has been written in FORTRAN to operate interactively at a computer terminal. We present a typical, though oversimplified, exchange between a physician or student and the computer.

At the start of the program the computer asks which function the physician wishes to exercise. The physician indicates by entering a 1 that he wishes to enter a series of findings on a patient. After referring to a code list, he enters, by code number, those findings that have already been determined.

```
FUNCTION?

1

ENTER SXS

7, 12, 14, 21, 56, 64, 74, 76, 89, 105, 134, 140, 150, 200, 220, 275, 280, 284, 289, 292, 298, 304, 309, 318, 491, 495, 497, 501, 503

ENTER SXS
```

If the physician wishes to check his input and obtain a list of the findings he entered, he requests function 4. He is given a choice of a complete list or, if he enters a 1, a list of demographic and all abnormal findings. In this case the physician has asked for the latter.

```
FUNCTION?
ENTER "1" FOR ABNORMAL HX FORM
 HIST
  7 AGE 40-49 YRS
 12 SEX MALE
 14 RACE WHITE
 56 FATIGUE, LETHARGY OR MALAISE
    PALPITATION
 76 PRECORDIAL PAIN
   BOWEL FUNCTION-DIARRHEA
PE
XRAY
LAB
 275 RBC INDICES HGB 7-12.9, MCV <80,
                           MCH < 30
 284 LYMPHOCYTES <20%
```

The physician then requests the listing of differential diagnoses and probabilities by entering function 5. The computer calculates the probability that the patient has each of the 40 diseases currently in the system and lists those with probability greater than 1%. The physician is able to compare this list of probabilities with his own

ANISOCYTOSIS & POIKILOCYTOSIS

clinical judgment. At this stage there is not enough information to give a high probability of any disease.

FUNCTION?

5 :

**DIFFERENTIAL DIAGNOSIS** 

- # 5 IRON DEFICIENCY ANEMIA 38.7% # 30 THALASSEMIA MINOR 9.1%
- # 2 ANEMIA OF MALABSORPTION 2.8%
- # 37 ANEMIA OF MALIG., NON-HEM. 1.3%

Because iron deficiency anemia has a relatively high score in the differential diagnosis, the physician asks the computer for the rationale behind that diagnosis by entering function 6 and the disease code number 5 for iron deficiency anemia. The computer prints out a list of the findings supporting the diagnosis and those opposing the diagnosis, in order of their significance. In this example there is only one finding in each category. However, the weight of each finding is shown as p/q for making the diagnosis or q/p for ruling out the diagnosis. For convenience, when p/q is less than one, the inverse,  $q_{i}p$ , is displayed. If either ratio is greater than 1000, its value is hown as \*\*\*\*\*\*\*\*\*.

**FUNCTION?** 

ENTER DISEASE NUMBER FOR P/Q RATIOS?

RECORDED SYMPTOM P/Q RATIOS FOR 5 IRON DEFICIENCY ANEMIA

P/Q FOR DIAGNOSIS

#2.0 # 275 RBC INDICES HGB 7-12.9, MCV

<80, MCH <30

OF AGAINST DIAGNOSIS 2.5 # 12 SEX MALE

If the physician thinks there is enough evidence to pursue the diagnosis of iron deficiency anemia, he may request a list of suggested findings to investigate. He does this by entering function 9 and the code number for the disease in question. Unrecorded findings that support or oppose the diagnosis are listed in order of p/q or q/p. The physician compares this list with his own judgment and decides on the priorities for further examinations.

FUNCTION?

ENTER DISEASE NUMBER FOR P/Q RATIOS?

UNRECORDED SYMPTOM P/Q RATIOS FOR 5 IRON DEFICIENCY ANEMIA

P/Q FOR DIAGNOSIS

980.0 # 345 BM IRON-ABSENT # 427 SERUM COPPER HIGH RESPONSE TO IRON-POSITIVE

SERUM IRON BINDING CAP (TOTAL) HIGH

BM CELLULARITY-

**INCREASED** 

FINGERNAILS-SPOONED OR BRITTLE

# 311 TARGET CELLS

10.0 # 321 RETICULOCYTE COUNT <1%

9.3 # 430 SERUM IRON LOW <70

# 197 TONGUE SMOOTH OR SORE

DYSPNEA

ACHLORHYDRIA-PRESENT 2.7 # 564

O/P AGAINST DIAGNOSIS

SERUM IRON BINDING CAP # 433 (TOTAL) LOW

SERUM IRON HIGH >130

# 348 BM IRON-INCREASED

# 325 RETICULOCYTE COUNT

> = 10%

RESPONSE TO IRON-

NEGATIVE

BM CELLULARITY-

DECREASED

# 337 BM MEGALOBLASTIC

5.0 # 426 SERUM COPPER NORMAL

After any or all of the additional tests suggested, or any other tests the physician wishes, have been performed, the physician may enter the additional finding codes into the computer through function 2.

FUNCTION?

ENTER SXS

435, 175, 311, 321, 430

**ENTER SXS** 

A revised differential diagnosis may then be requested through function 5. The findings, now including low serum iron and high iron binding capacity, have made the diagnosis of iron deficiency anemia virtually certain. At the same time thalassemia minor has appeared on the list with relatively high probability. Further studies and interaction with the computer would be required to pursue this possibility.

**FUNCTION?** 

**DIFFERENTIAL DIAGNOSIS** 

5 IRON DEFICIENCY ANEMIA 100.0% # 30 THALASSEMIA MINOR 89.9% # 37 ANEMIA OF MALIG., NON-HEM. 28.0%

2.8%

2 ANEMIA OF MALABSORPTION

From examples such as these we have concluded that HEME is useful in teaching hematology and has potential as an aid in diagnosis and as a means of studying the diagnostic process itself.

## **Testing of program**

Immediately after the HEME program was written, it was exercised on a series of 31 cases of hematologic disease selected from the medical record library of New York Hospital. After each case was analyzed by the work group responsible for HEME, a subjective judgment was made about how well the program would have performed as an aid to a physician in the diagnostic process. In this study, 14 cases were rated excellent, seven good, one fair, three poor, and six not evaluable because the correct diagnoses were not yet in the system.

Encouraged by these results, we proceeded to seek experience with HEME as an aid to diagnosis and as a teaching tool. R. Strauss, who was a fourth-year medical student at the time, followed 30 hematology patients at the New York Hospital from time of admission until diagnosis was accepted. Taking information from the charts and from conferences with responsible physicians, he entered data into the program at frequent intervals, monitored the output of suggestions of diagnoses and findings to test, and compared these results with the decisions and procedures specified by the responsible physicians. In the course of this project, he found that in many instances there was a good correlation between the results coming out of the computer and the thinking of the physicians responsible for the patients. Other cases exposed correctable errors and the absence of important diseases or findings from the system.

Most recently HEME has been used experimentally under the direction of Dr. R. Friedman at the University of Wisconsin School of Medicine as an aid in the teaching of hematology. Students have found it instructive and useful, and staff hematologists have been impressed with its teaching potential. They find that it encourages students to take account of previously unconsidered diagnoses and often leads to lively teaching sessions. In the course of this experiment, the HEME analyses of 44 cases were evaluated. A record was made of the diagnoses suggested by the program after findings observed in the initial study were entered. This process was repeated after the results of all relevant tests had been reported and a "correct" diagnosis was accepted by the physicians responsible for the patient. For each case, we observed the ranking of the "correct" diagnosis by HEME, and these observations are summarized in Table 3.

In all these experiments, it was demonstrated that HEME has fine potential as an aid to diagnosis and as a teaching device. In almost every case it stimulated thought in the right direction and jogged the memory

Table 3 Results of trial of HEME as teaching aid at University of Wisconsin School of Medicine.

Ranking of "correct" diagnosis by HEME	Initial study	Final decision
1	16	25
2	7	8
3	8	1
4	0	2
5	5	0
>5	3	2
Correct diagnosis not in HEME	5	5
Case not yet complete		1

about diagnoses and tests to consider. The p/q ratio was found to be a natural and intuitively comfortable way to think about the relevance of a finding to a disease, both in the initial assignment of p and q and in the interpretation of the analysis by users of the program. Exercising the program revealed a number of correctable errors as well as diagnoses and additional findings that need to be added to the system. These results lead to the conclusion that more effort is required and is definitely justified.

#### **Discussion**

In this paper we have described a Bayesian program for the diagnosis of hematologic diseases. It is distinguished from other Bayesian programs by the fact that each disease is analyzed individually to determine the probability that the patient has the disease vs the probability that he does not and by the property of combining initial clinical judgment with accumulating data in a self-improving mode. This program provides a framework whereby the intensive work of a few able physicians concentrating on a group of medical diagnostic problems can produce a system of value to many physicians and the communities they serve. The system can be used to train medical personnel, assist in diagnostic decisions, and record patient data in coherent form.

The version of Bayes' Theorem used in HEME requires far fewer probabilities of findings in diseases than does the usual version. Since each disease is analyzed separately, the p and q need be entered only for those findings relevant to the diagnosis of that disease. Inherent in the system is the capacity to grow and improve itself in three ways. New diseases may be added without changing the rest of the system; new findings relevant to one or more diseases may be added with only minor changes; and the probabilities required for Bayes' Theorem may be modified automatically as data are accumulated.

# **Acknowledgments**

The work described in this paper was supported in part under Contract PH-43-67-1337 with the National Institutes of Health, Public Health Service, Department of Health, Education, and Welfare. Dr. S. Allen, Dr. M. Lipkin, Dr. B. J. Davis, Dr. L. Leveridge, Dr. R. Friedman, Dr. R. Craig, Dr. K. Peele, Dr. G. Ubogy, Dr. L. Frenkel, Dr. R. Strauss and Mr. G. Novick also contributed to the development of this program. A part of this paper was presented before the American Clinical and Climatological Association on October 21, 1974, in Williamsburg, Virginia.

#### References

- M. Lipkin and J. D. Hardy, "Differential Diagnosis of Hematologic Diseases Aided by Mechanical Correlation of Data," *Report NADC-MA-5505*, U.S. Naval Air Development Center, Johnsville, Pa., 1955.
- M. Lipkin and J. D. Hardy, "Differential Diagnosis of Hematologic Diseases Aided by Mechanical Correlation of Data," Science 125, 551 (1957).
- M. Lipkin and J. D. Hardy, "Mechanical Correlation of Data in Differential Diagnosis of Hematological Diseases," J. Am. Med. Assoc. 166, 113 (1958).
- V. K. Zworykin, R. Lane, M. Lipkin, R. Ebald, R. Engle, and B. Davis, "A Bizmac Program for Medical Data Processing," *Medical Data Processing Demonstration*, Radio Corporation of America, Camden, NJ, December 13, 1957.
- Corporation of America, Camden, NJ, December 13, 1957.
  5. R. Ebald and R. Lane, "Digital Computers and Medical Logic," *IRE Trans. Med. Electron* 7, 283 (1960).
- M. Lipkin, "Correlation of Data with a Digital Computer in the Differential Diagnosis of Hematologic Diseases," IRE Trans. Med. Electron 7, 243 (1960).
- M. Lipkin, R. L. Engle, Jr., B. J. Davis, V. K. Zworykin, R. Ebald, M. Sendrow, and C. Berkley, "Digital Computer as Aid to Differential Diagnosis," Arch. Int. Med. 108, 56 (1961).
- M. Lipkin, "Digital and Analogue Computer Methods Combined to Aid in the Differential Diagnosis of Hematological Diseases," Circ. Res. 11, 607 (1962).
- M. A. Atamer, Blood Diseases, Grune and Stratton Inc., New York, 1963.
- R. L. Engle, Jr., M. Lipkin, B. J. Flehinger, B. J. Davis, and L. L. Leveridge, "Computer-Assisted Differential Diagnosis of Hematologic Diseases," Report on work accomplished under Contract #PH 43-67-1337 with NIH, PHS, HEW, 1969.
- M. Lipkin, R. L. Engle, Jr., B. J. Flehinger, L. J. Gerstman, and M. A. Atamer, "Computer-Aided Differential Diagnosis of Hematologic Diseases, *Proc. NY Acad. Sci.* 161, 670 (1969).
- R. L. Engle, Jr., M. Lipkin, and B. J. Flehinger, "Computer-aided Differential Diagnosis of Hematologic Diseases (A Bayesian probability model)," Computer Diagnosis and Diagnostic Methods, edited by J. A. Jacquez, Charles C. Thomas, Springfield, Ill., 1972, p. 279.

- R. L. Engle, Jr. and B. J. Flehinger, "Computer-oriented Thinking in Hematology," *Clinically Oriented Documenta*tion of Laboratory Data, edited by E. R. Gabrieli, Academic Press, New York, 1972, p. 311.
- 14. R. L. Engle, Jr. and B. J. Flehinger, "Computer-aided Differential Diagnosis of Hematologic Diseases: A Bayesian Probability Model," *Modern Concepts in Hematology*, edited by G. Izak and S. M. Lewis, Academic Press, New York, 1972, p. 265.
- R. S. Ledley and L. B. Lusted, "Reasoning Foundations of Medical Diagnosis: Symbolic Logic, Probability, and Value Theory Aid Our Understanding of How Physicians Reason," *Science* 130, 9 (1959).
- Reason," Science 130, 9 (1959).

  16. H. R. Warner, A. F. Toronto, G. Veasey, and R. Stephenson, "A Mathematical Approach to Medical Diagnosis: Application to Congenital Heart Disease," J. Am. Med. Assoc. 177, 177 (1961).
- H. R. Warner, A. F. Toronto, and L. G. Veasey, "Experience with Bayes' Theorem for Computer Diagnosis of Congenital Heart Disease," Ann. NY Acad. Sci. 115, 558 (1964)
- A. F. Toronto, L. G. Veasey, and H. R. Warner, "Evaluation of a Computer Program for Diagnosis of Congenital Heart Disease," *Progr. Cardiovascular Diseases* 5, 362 (1963).
- 19. G. A. Gorry and G. O. Barnett, "Sequential Diagnosis by Computer," J. Am. Med. Assoc. 205, 849 (1968).
- D. H. Gustafson, J. J. Kestly, J. H. Greist, and N. M. Jensen, "Initial Evaluation of a Subjective Bayesian Diagnostic System," *Health Services Res.* 6, 204 (1971).
- C. A. Nugent, H. R. Warner, J. T. Dunn, and F. H. Tyler, "Probability Theory in Diagnosis of Cushing's Syndrome," *J. Clin. Endocrinol Metab.* 24, 621 (1964).
- 22. H. Raiffa and R. Schlaifer, Applied Statistical Decision Theory, Harvard Business School, Boston (1961).
- 23. M. L. Bykhovskiy, "Probability Dependence of Symptoms in the Problem of Diagnosis," Machine Diagnosis and Information Retrieval in Medicine in the USSR, edited by A. A. Vishnevskiy, I. I. Artobolevskiy, and M. L. Bykhovskiy, DHEW Pub No (NIH) 73-424, US Dept. of Health, Education, and Welfare, 1973.
- M. J. Norusis and J. A. Jacquez, "Diagnosis, I. Symptom Nondependence in Mathematical Models of Diagnosis," Comput. and Biomed. Res. 8, p. 156 (1975).
- M. J. Norusis and J. A. Jacquez, "Diagnosis, II. Diagnostic Models Based on Attribute Clusters: A Proposal and Comparisons," Comput. and Biomed. Res. 8, p. 173 (1975).

Received May 1, 1975

B. J. Flehinger is located at the IBM Thomas J. Watson Research Center, Yorktown Heights, New York. Dr. R. L. Eagle, Jr., is located at Cornell University Medical College and the New York Hospital, New York, N.Y.